

Attorney Docket No.: RTS-0066
Inventors: Bennett et al.
Serial No.: 09/490,208
Filing Date: January 24, 2000
Page 2

wherein said antisense compound specifically hybridizes with and inhibits the expression of human inducible nitric oxide synthase.

3. (amended) [The] An antisense compound [of claim 2 wherein the antisense oligonucleotide has a sequence] up to 30 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO: 19, 20, 21, 23, 24, 29, 30, 31, 32, 33, 36, 38, 42, 43, 44, 45, 46, 48, 49, 50, 52, 53, 54, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 96, 98, 99, 100, 101, 103, 105, 106, 107, 109, 113, 117, 118, 125, 127, 131, 132, 135, 137, 138, 140, 148, 152, 153, 168 or 180 which inhibits the expression of human inducible nitric oxide synthase.

10. (amended) The antisense compound of claim [1] 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Please cancel claims 15-20.

Please add the following new claims:

--21. The antisense compound of claim 3 which is an

Attorney Docket No.: RTS-0066
Inventors: Bennett et al.
Serial No.: 09/490,208
Filing Date: January 24, 2000
Page 3

22. The antisense compound of claim 21 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

23. The antisense compound of claim 22 wherein the modified internucleoside linkage is a phosphorothioate linkage.

24. The antisense compound of claim 21 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

25. The antisense compound of claim 24 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

26. The antisense compound of claim 21 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

27. The antisense compound of claim 26 wherein the modified nucleobase is a 5-methylcytosine.

28. The antisense compound of claim 21 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Attorney Docket No.: **RTS-0066**
Inventors: **Bennett et al.**
Serial No.: **09/490,208**
Filing Date: **January 24, 2000**
Page 4

29. A composition comprising the antisense compound of claim 3 and a pharmaceutically acceptable carrier or diluent.

30. The composition of claim 29 further comprising a colloidal dispersion system.

31. The composition of claim 29 wherein the antisense compound is an antisense oligonucleotide.

32. A method of inhibiting the expression of inducible nitric oxide synthase in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 3 so that expression of inducible nitric oxide synthase is inhibited.--

REMARKS

Claims 1-20 are pending in the instant application. Claims 15-20 were subject to a restriction requirement have been withdrawn from consideration. Claims 1, 2 and 4-14 have been rejected. Claim 3 has been objected to. Claims 1, 3 and 10 have been amended. Claims 15-20 have been canceled. New claims 21-32 have been added in light of the amendment making claim 3 independent; dependent claims 21-32 are dependent on claim 3. The following is a brief description of the claims: